On the basis of the amyloid hypothesis of Alzheimer’s Disease (AD), most of the clinical trials conducted have concerned Aβ clearing therapy. Because of multiple failures in anti-amyloid clinical drug trials, more attention has been drawn to therapies targeted at tau in AD drug development. Disease-modifying therapies for AD and other tauopathies are targeting post-translational modifications, tau aggregation, microtubule stabilization, regulation of tau expression and tau clearance (immunotherapies). ClinicalTrials.gov currently lists about 120 studies targeting tau as a treatment for … Continue reading Tau Clinical Trials – What can be learned from failure?
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed